Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
RESEARCH TOOLSreports
Holding DBVT?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$1.11Last Year’s EPS
-$1.2Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -17.14%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with significant progress in Viaskin Peanut development and financial management. However, regulatory challenges and increased operating expenses pose some concerns. The overall sentiment is cautiously optimistic with a positive tilt due to successful trial milestones and extended cash runway.Company Guidance
During the DBV Technologies Q2 2024 earnings call, the company provided several key updates on its development programs and financial outlook. DBV is advancing its Viaskin Peanut candidate for treating peanut allergies in children aged 1 to 7. The VITESSE Phase III trial for children aged 4 to 7 is progressing well, with patient enrollment expected to complete by the end of Q3 2024. The company is also addressing the FDA's feedback on its COMFORT Toddlers supplemental safety study, which supports the Biologics License Application for the 1 to 3 age group. Additionally, DBV Technologies has extended its cash runway into Q1 2025 due to cost-saving measures, despite a net loss of $60.5 million in H1 2024. The company remains focused on achieving regulatory approval and advancing its clinical trials, with anticipated milestones set for the remainder of the year.Viaskin Peanut Development Progress
Successful results from the Phase III efficacy study, EPITOPE, for toddlers aged 1 to 3 years met its primary endpoint. Enrollment for the VITESSE Phase III trial in children aged 4 to 7 years is expected to complete by the end of Q3 2024.
Cash Runway Extension
Due to cost-saving measures, DBV Technologies has extended its cash runway into Q1 of 2025, an extension from the previous estimate of year-end 2024.
Financial Efficiency
Operating income for the first semester of 2024 reached $2.6 million, with efforts to maximize efficiency and maintain disciplined cash management.
---
DBVT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DBVT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $3.85 | $3.70 | -3.90% |
| Jul 30, 2024 | $4.74 | $4.84 | +2.11% |
| May 07, 2024 | $6.80 | $6.94 | +2.06% |
| Mar 07, 2024 | $8.26 | $8.58 | +3.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does DBV Technologies SA - American (DBVT) report earnings?
DBV Technologies SA - American (DBVT) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is DBV Technologies SA - American (DBVT) earnings time?
DBV Technologies SA - American (DBVT) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DBVT EPS forecast?
DBVT EPS forecast for the fiscal quarter 2024 (Q4) is -$1.11.
---